| Literature DB >> 27562713 |
Stephanie W Edmonds1,2, Peter Cram3,4, Yiyue Lou5, Michael P Jones5,6, Douglas W Roblin7,8, Kenneth G Saag9, Nicole C Wright10, Fredric D Wolinsky11,12,13.
Abstract
BACKGROUND: Undiagnosed, or diagnosed and untreated osteoporosis (OP) increases the likelihood that falls result in hip fractures, decreased quality of life (QOL), and significant medical expenditures among older adults. We tested whether a tailored dual energy x-ray absorptiometry (DXA) test result letter and an accompanying educational bone-health brochure affected patient satisfaction, QOL, or OP knowledge.Entities:
Keywords: Dual-energy x-ray absorptiometry; Health education; Osteoporosis; Quality of health care; Quality of life
Mesh:
Year: 2016 PMID: 27562713 PMCID: PMC5000520 DOI: 10.1186/s12891-016-1227-0
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1CONSORT Flow Diagram of PAADRN Study
Baseline characteristics by treatment group among the PAADRN participants (N = 7,749)
| Intervention ( | Control ( |
| |
|---|---|---|---|
| Sociodemographics | |||
| Age, mean (SD) | 66.5 (8.4) | 66.7 (8.2) | 0.2461 |
| Women, N (%) | 3,259 (83.6) | 3,230 (83.9) | 0.7502 |
| Race/Ethnicity | |||
| White, N (%) | 2,981 (76.5) | 2,954 (76.7) | 0.6992 |
| Black, N (%) | 842 (21.6) | 814 (21.1) | |
| Other, N (%) | 75 (1.9) | 83 (2.2) | |
| Education | |||
| Some high school, N (%) | 161 (4.2) | 140 (3.7) | 0.7492 |
| Completed high school, N (%) | 819 (21.2) | 836 (21.9) | |
| Some college, N (%) | 1,290 (33.4) | 1,269 (33.2) | |
| Completed college, N (%) | 785 (20.3) | 762 (19.9) | |
| Graduate school, N (%) | 809 (20.9) | 814 (21.3) | |
| Comorbid Conditions | |||
| COPD, N (%) | 259 (6.7) | 265 (6.9) | 0.6802 |
| Depression, N (%) | 902 (23.2) | 885 (23.0) | 0.8782 |
| Prostate cancer, N (%) | 117 (18.3) | 88 (14.2) | 0.0482 |
| Breast cancer, N (%) | 416 (10.7) | 612 (15.9) | <0.0012 |
| Health Habits | |||
| Current smoker, N (%) | 295 (7.6) | 295 (7.7) | 0.8732 |
| Past smoker, N (%) | 1,478 (37.9) | 1,388 (36.1) | 0.0952 |
| Current alcohol user, N (%) | 1,768 (45.4) | 1,808 (47.0) | 0.1572 |
| Self-reported Health Status | |||
| Excellent, N (%) | 445 (11.4) | 494 (12.8) | 0.3292 |
| Very Good, N (%) | 1,443 (37.1) | 1,373 (35.7) | |
| Good, N (%) | 1,280 (32.9) | 1,253 (32.6) | |
| Fair, N (%) | 571 (14.7) | 566 (14.7) | |
| Poor, N (%) | 150 (3.9) | 159 (4.1) | |
| Bone Health | |||
| Prior DXA, N (%) | 2,606 (66.9) | 2,590 (67.3) | 0.7192 |
| History of OP, N (%) | 794 (20.6) | 909 (23.8) | 0.0012 |
| History of OP treatment, N (%) | 1,438 (36.9) | 1,502 (39.0) | 0.0552 |
| Glucocorticoids Use, N (%) | 593 (15.2) | 576 (15.0) | 0.7532 |
| Study DXA Results | |||
| Normal, N (%) | 1,133 (29.1) | 990 (25.7) | 0.0012 |
| Low BMD, N (%) | 2,052 (52.6) | 2,066 (53.6) | |
| Osteoporosis, N (%) | 713 (18.3) | 795 (20.6) | |
| Lowest T-Score, mean (SD) | -1.62 (1.1) | -1.55 (1.1) | 0.0021 |
| 10-year Fracture Risk (FRAX), mean (SD) | 12.0 (9.2) | 12.3 (9.1) | 0.1011 |
1 P-value from Two-sample T-Test
2 P-value is from Pearson Chi-square Test
Unadjusted means (SDs) on all 7,749 PAADRN participants at baseline, 12- and 52-weeks using intention-to-treat (ITT)
| Baseline | 12-weeks | 52-weeks | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Intervention | Control |
| Intervention | Control |
| Intervention | Control |
| |
| OP care satisfaction (5-25) | 18.9 (2.7)a | 19.1 (2.8)a | 0.011 | 21.1 (3.2) | 20.1 (4.0) | <0.001 | 21.1 (3.2) | 20.5 (3.8) | <0.001 |
| Quality of life | |||||||||
| SF-1 (15/30/80/90/95; poor to excellent) | 75.2 (23.8) | 75.1 (24.1) | 0.925 | 74.6 (24.2) | 74.8 (24.4) | 0.746 | 74.5 (24.1) | 75.4 (23.8) | 0.132 |
| EuroQol EQ5D-3 L utility score (0-1) | 0.8 (0.2) | 0.8 (0.2) | 0.676 | 0.8 (0.2) | 0.8 (0.2) | 0.547 | 0.8 (0.2) | 0.8 (0.2) | 0.72 |
| EuroQol visual analog scale of Euroqol (0-100) | 78.1 (16.7) | 78.3 (16.7) | 0.590 | 77.5 (17.6) | 78.2 (17.2) | 0.083 | 77.7 (17.6) | 78.2 (17.1) | 0.244 |
| OPc knowledge – scale score (0-10) | 7.5 (1.9) | 7.5 (1.8) | 0.712 | 7.8 (1.6) | 7.8 (1.6) | 0.759 | 7.8 (1.6) | 7.8 (1.6) | 0.476 |
| Biological risk factors | 2.3 (0.9) | 2.3 (0.9) | 0.345 | 2.5 (0.8) | 2.4 (0.8) | 0.495 | 2.5 (0.8) | 2.5 (0.8) | 0.724 |
| Lifestyle risk factors | 1.8 (0.4) | 1.8 (0.4) | 0.807 | 1.9 (0.3) | 1.9 (0.4) | 0.089 | 1.9 (0.4) | 1.9 (0.4) | 0.327 |
| Consequences | 1.7 (0.6) | 1.7 (0.6) | 0.688 | 1.7 (0.5) | 1.7 (0.5) | 0.471 | 1.7 (0.5) | 1.7 (0.5) | 0.485 |
| Prevention and treatment | 1 (0.8) | 1 (0.8) | 0.974 | 1 (0.8) | 1 (0.8) | 0.726 | 0.9 (0.8) | 0.9 (0.8) | 0.832 |
aThese are means and standard deviations among those who had a DXA prior to baseline interview
Regression coefficients for the intervention on satisfaction with OP care, QOL, and OP knowledge from the intention-to-treat (ITT) random effects models (N = 7,749)
| 12-weeks | 52-weeks | ||||
|---|---|---|---|---|---|
| Crude | Adjusted | Crude | Adjusted | ||
| OP care satisfaction (5-25)a | Estimate | 1.02* | 1.02* | 0.61* | 0.62* |
| 95 % CI | ( 0.82, 1.22) | ( 0.83, 1.22) | ( 0.40, 0.82) | ( 0.43, 0.82) | |
| Quality of life | |||||
| SF-1 (15/30/80/90/95; poor to excellent) | Estimate | 0.21 | -0.05 | -0.37 | -0.66 |
| 95 % CI | ( -0.74, 1.16) | ( -0.93, 0.83) | ( -1.33, 0.58) | ( -1.52, 0.21) | |
| EuroQol EQ5D-3 L, utility score (0-1) | Estimate | 0.00 | 0.00 | 0.00 | 0.00 |
| 95 % CI | ( -0.01, 0.01) | ( -0.01, 0.00) | ( -0.01, 0.01) | ( -0.01, 0.01) | |
| EuroQol visual analog scale (0-100) | Estimate | -0.44 | -0.59 | -0.42 | -0.47 |
| 95 % CI | ( -1.13, 0.26) | ( -1.23, 0.05) | ( -1.18, 0.33) | ( -1.18, 0.24) | |
| OP knowledge scale score (0-10) | Estimate | 0.01 | 0.01 | 0.04 | 0.03 |
| 95 % CI | ( -0.07, 0.1) | ( -0.06, 0.08) | ( -0.03, 0.12) | ( -0.04, 0.09) | |
*p < 0.0005
aThese are models on outcomes at 12-weeks and 52-weeks without adjustment for baseline values